Electroacupuncture reduces chronic itch via cannabinoid CB1 receptors in the ventrolateral periaqueductal gray

Chronic itch severely reduces the quality of life of patients. Electroacupuncture (EA) is widely used to treat chronic itch. However, the underlying mechanism of this therapeutic action of EA is largely unknown. Cannabinoid CB1 receptors in the ventrolateral periaqueductal gray (vlPAG) mediate the a...

Full description

Saved in:
Bibliographic Details
Main Authors: Wen-Qiang Ge (Author), Ou-Yan (Author), Chao Chen (Author), Hong Zhang (Author), Xiao-Yu Wang (Author), Xin Liu (Author), Li Li (Author), Yu-Ye Lan (Author), Chen-Nan Li (Author), Jia-Can Sun (Author), Run-Lin Shi (Author), Zi-Yue Dou (Author), Hui-Lin Pan (Author), Hong-Ping Li (Author), Xiang-Hong Jing (Author), Man Li (Author)
Format: Book
Published: Frontiers Media S.A., 2022-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8fc84d33a7ce4ab6bf4141e39ef57f37
042 |a dc 
100 1 0 |a Wen-Qiang Ge  |e author 
700 1 0 |a Ou-Yan  |e author 
700 1 0 |a Chao Chen  |e author 
700 1 0 |a Hong Zhang  |e author 
700 1 0 |a Xiao-Yu Wang  |e author 
700 1 0 |a Xin Liu  |e author 
700 1 0 |a Li Li  |e author 
700 1 0 |a Yu-Ye Lan  |e author 
700 1 0 |a Chen-Nan Li  |e author 
700 1 0 |a Jia-Can Sun  |e author 
700 1 0 |a Run-Lin Shi  |e author 
700 1 0 |a Zi-Yue Dou  |e author 
700 1 0 |a Hui-Lin Pan  |e author 
700 1 0 |a Hong-Ping Li  |e author 
700 1 0 |a Xiang-Hong Jing  |e author 
700 1 0 |a Man Li  |e author 
245 0 0 |a Electroacupuncture reduces chronic itch via cannabinoid CB1 receptors in the ventrolateral periaqueductal gray 
260 |b Frontiers Media S.A.,   |c 2022-09-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2022.931600 
520 |a Chronic itch severely reduces the quality of life of patients. Electroacupuncture (EA) is widely used to treat chronic itch. However, the underlying mechanism of this therapeutic action of EA is largely unknown. Cannabinoid CB1 receptors in the ventrolateral periaqueductal gray (vlPAG) mediate the analgesic effect of EA. Using a dry skin-induced itch model in mice, we determined whether EA treatment reduces chronic itch via CB1 receptors in the vlPAG. We showed that the optimal inhibitory effect of EA on chronic itch was achieved at the high frequency and high intensity (100 Hz and 3 mA) at "Quchi" (LI11) and "Hegu" (LI14) acupoints, which are located in the same spinal dermatome as the cervical skin lesions. EA reversed the increased expression of CB1 receptors in the vlPAG and decreased the concentration of 5-hydroxytryptamine (5-HT) in the medulla oblongata and the expression of gastrin-releasing peptide receptors (GRPR) in the cervical spinal cord. Furthermore, knockout of CB1 receptors on GABAergic neurons in the vlPAG attenuated scratching behavior and the 5-HT concentration in the medulla oblongata. In contrast, knockout of CB1 receptors on glutamatergic neurons in the vlPAG blocked the antipruritic effects of EA and the inhibitory effect of EA on the 5-HT concentration in the medulla oblongata. Our findings suggest that EA treatment reduces chronic itch by activation of CB1 receptors on glutamatergic neurons and inhibition of CB1 receptors on GABAergic neurons in the vlPAG, thereby inhibiting the 5-HT release from the medulla oblongata to GRPR-expressing neurons in the spinal cord. Our findings suggest that EA attenuates chronic itch via activating CB1 receptors expressed on glutamatergic neurons and downregulating CB1 receptors on GABAergic neurons in the vlPAG, leading to the reduction in 5-HT release in the rostroventral medulla and GRPR signaling in the spinal cord. Our study not only advances our understanding of the mechanisms of the therapeutic effect of EA on chronic itch but also guides the selection of optimal parameters and acupoints of EA for treating chronic itch. 
546 |a EN 
690 |a Acupuncture 
690 |a chronic itch 
690 |a CB1 receptors 
690 |a PAG 
690 |a glutamate 
690 |a GABA 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 13 (2022) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fphar.2022.931600/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/8fc84d33a7ce4ab6bf4141e39ef57f37  |z Connect to this object online.